ArticleCureus2025
Autologous Skin Cell Suspension Monotherapy Without Split-Thickness Skin Grafting for Deep Dermal Burns in Pediatric Patients: A Case Series.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Clinical and Economic Burden of Autologous Skin Grafting for Nonthermal Full-Thickness Wounds Across Care Settings: A US Retrospective Claims Study.Advances in therapy · 2026Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
RECELL® autologous cell harvesting device (AVITA Medical, Inc., Santa Clarita, California, United States) is a non-cultured autologous skin cell suspension (ASCS) device that rapidly processes a small sample of the patient's own skin into a cell suspension that can be sprayed onto large burn wounds. The ASCS system is considered to be effective for treating burns in children, especially because it minimizes new scars caused by skin harvesting; however, there are very few reports on ASCS monotherapy without autologous split-thickness skin grafting in patients under three years of age. This report describes three cases of deep dermal burn in patients under the age of three years treated with ASCS monotherapy. The cases highlight the advantages of ASCS monotherapy, including expedited healing, reduced burden of wound care, and minimized scarring from skin harvesting. In ASCS monotherapy, challenges remain, including the fragility of the engrafted cells, the small but unavoidable need for skin harvesting, postoperative scarring, and high treatment costs. This report highlights the need for ongoing accumulation of case studies to refine treatment protocols and emphasizes the importance of extended follow-up to evaluate long-term outcomes, including the impact of growth on scar formation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.